Psoriasis in Pediatrics
https://doi.org/10.15690/vsp.v19i6.2150
Abstract
Psoriasis is one of the most debatable topics in modern dermatology among the wide range of other dermatological diseases in childhood. The article provides current data on the epidemiology of psoriasis, its clinical features in different age groups, its triggering factors, differential diagnostics, possible comorbid conditions, as well as the quality of life of patients and their relatives.
Supporting agencies: Not specified
About the Authors
Andrey L. Bakulev
Saratov State Medical University n.a. V.I. Razumovsky
Russian Federation
Saratov
Disclosure of interest:
Russian Federation
Saratov
Disclosure of interest:
Andrey L. Bakulev — conducting clinical trials in cooperation with MSD, Jansen, AbbVie, LEO Pharma, UCB, BIOCAD, Dr. Reddy's Laboratories Ltd., Novartis, AMGen, Galderma, VEROPHARM, Pfizer, UCB. Expert data evaluation for Eli Lilly, Jansen, AbbVie, LEO Pharma, UCB, BIOCAD, Novartis, AMGen, Galderma, Zeldis Pharma. Reading reports for Eli Lilly, Bayer, MSD, Jansen, AbbVie, LEO Pharma, UCB, BIOCAD, Dr. Reddy's Laboratories Ltd., Novartis, Galderma, VEROPHARM, Pfizer, JADRAN (JGL), Zeldis Pharma
Ekaterina E. Talnikova
Saratov State Medical University n.a. V.I. Razumovsky
Russian Federation
Saratov
Disclosure of interest:
Russian Federation
Saratov
Disclosure of interest:
Ekaterina E. Talnikova confirmed the absence of a reportable conflict of interests
References
1. Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: Evolving perspectives. Pediatric Dermatology. 2018;35(2): 170–181. doi: 10.1016/j.jaad.2016.09.014.
2. Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in child ren and adolescents: Diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373–384. doi: 10.1007/s40272-015-0137-1.
3. Relvas M, Torres T. Pediatric psoriasis. Am J Clin Dermatol. 2017;18(6):797–811. doi: 10.1007/s40257-017-0294-9.
4. Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2): 377–385. doi: 10.1038/jid.2012.339.
5. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–1541. doi: 10.1001/archderm.141.12.1537.
6. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–178. doi: 10.1046/j.1525-1470.2000.01746.x.
7. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3): 633–636. doi: 10.1111/j.1365-2133.2009.09593.
8. Beylot C, Puissant A, Bioulac P, et al. Particular clinical features of psoriasis in infants and children. Acta Derm Venereol Suppl (Stockh). 1979;87:95–97. doi: 10.2340/00015555-0306.
9. Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: A population-based study. J Am Acad Dermatol. 2010;62(6):979–987. doi: 10.1016/j.jaad.2009.07.029.
10. Dogra S, Bishnoi A. Childhood psoriasis: What is new and what is news. Indian J Paediatr Dermatol. 2018;19:308–314. doi: 10.4103/ijpd.ijpd_72_18.
11. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi: 10.1016/s0140-6736(07)61128-3.
12. Altobelli E, Petrocelli R, Marziliano C, et al. Family history of psoriasis and age at disease onset in Italian patients with psoriasis. Br J Dermatol. 2007;156(6):1400–1401. doi: 10.1111/j.1365-2133.2007.07906.x.
13. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi: 10.1016/j.jaad.2019.08.049.
14. Pinson R, Sotoodian B, Fiorillo L, et al. Psoriasis in children. Psoriasis (Auckl). 2016;6:121–129. doi: 10.2147/ptt.s87650.
15. Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30(4):424–428. doi: 10.1111/pde.12072.
16. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4–5): 490–495. doi: 10.1016/j.autrev.2014.01.008.
17. Megna M, Napolitano M, Balato A, et al. Psoriasis in children: a review. Curr Pediatr Rev. 2015;11(1):10–26. doi: 10.2174/1573400511666150504125456.
18. Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis. Br J Dermatol. 2009;161(2):484–486. doi: 10.1111/j.1365-2133.2009.09276.x.
19. Becker L, Tom WL, Eshagh K, et al. Excess Adiposity Preceding Pediatric Psoriasis. JAMA Dermatol. 2014;150(5):573–574. doi: 10.1001/jamadermatol.2014.324.
20. Kwa L, Kwa MC, Silverberg JI. Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States. J Am Acad Dermatol. 2017;77(6):1023–1029. doi: 10.1016/j.jaad.2017.08.034.
21. Boehncke W-H, Boehncke S, Tobin A-M, et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi: 10.1111/j.1600-0625.2011.01261.x.
22. Paller AS, Mercy K, Kwasny MJ, et al. Association of Pediatric Psoriasis Severity With Excess and Central Adiposity: An International Cross-Sectional Study. JAMA Dermatol. 2013;149(2): 166–176. doi: 10.1001/jamadermatol.2013.1078.
23. Tom WL, Playford MP, Admani S, et al. Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. J Invest Dermatol. 2016;136(1):67–73. doi: 10.1038/jid.2015.385.
24. Di Costanzo L, Fattorusso V, Mozzillo E, et al. Psoriasis in children with type 1 diabetes: A new comorbidity to be considered? Acta Diabetol. 2017;54(8):803–804. doi: 10.1007/s00592-017-1000-3.
25. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392. doi: 10.2165/00128071-200506060-00005.
26. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997; 2(4):525–537. doi: 10.1177/135910539700200409.
27. Russo P, Ilchef R, Cooper A. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155–161. doi: 10.1111/j.1440-0960.2004.00078.x.
28. Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657.e2. doi: 10.1016/j.jaad.2011.11.94.
29. Zappel K, Sterry W, Blume-Peytavi U. Therapy options for psoriasis in childhood and adolescence. J Dtsch Dermatol Ges. 2004; 2(5):329–342. doi: 10.1046/j.1439-0353.2004.04061.x.
30. Tollefson MM, Megha M, Schoch JJ, Eton DT. Impact of childhood psoriasis on parents of affected children. J Am Acad Dermatol. 2017;76(2):286–289.e5. doi: 10.1016/j.jaad.2016.09.014.
31. Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485–492. doi: 10.1007/s00431-011-1587-2.
32. Osier E, Wang AS, Tollefson MM, et al. Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol. 2017;153(7): 698–704. doi: 10.1001/jamadermatol.2017.0499.
Review
For citations:
Bakulev A.L., Talnikova E.E. Psoriasis in Pediatrics. Current Pediatrics. 2020;19(6):496-499. (In Russ.) https://doi.org/10.15690/vsp.v19i6.2150
Views:
815
Email this article 
